Search
Sponsor opportunities
The European Hematology Association (EHA) invites you to support the EHA Research Conference 2025, titled "Transcriptional control and chromatin alterations in normal and abnormal hematopoiesis"
This meeting enables the industry to network with delegates, demonstrate their products and present their latest material…
European Reference Networks, a unique opportunity to take collaboration and patient care in hematology to the next level, was a core topic at EHA 2016
On Saturday 11 June, a session in the Patient Advocacy Track focused on the emerging European Reference Networks (ERNs).
Read moreMeet Achille Iolascon, our Volunteer of the Month
Can you tell us what you do for EHA and when you started?
I serve the EHA as chairman of the Study working group on “Red cells and iron” since June 2014.
Meet Achille Iolascon, our Volunteer of the Month
Can you tell us what you do for EHA and when you started?
I serve the EHA as chairman of the Study working group on “Red cells and iron” since June 2014.
Brussels Declaration on the Recognition of Professional QualificationsThe future of the Harmonisation of the Haematology Curriculum in Europe
On the occasion of the meeting, there was unanimous support for the
“Brussels Declaration on the Recognition of Professional Qualifications” that follows:
The mobility of haematology trainees is of the utmost importance.
SWG Preceptorship Program
Funding to enable an SWG create its own preceptorship—and promote learning and innovation in our community. The call for proposals is open until 12:00 CEST on March 28, 2025. Apply now.
Read moreGreat new opportunity for the YoungEHA community!
Great new opportunity for the YoungEHA community!
by Dr Nuno Borges, YoungEHA committee
The European Medicines Agency (EMA) has launched the 'Collaborating Expert Programme' - an initiative which aims to increase co-operation between European countries to improve research into medicinal products.…
Reduction of chemotherapy and PET-guided radiotherapy in advanced-stage Hodgkin lymphoma: the GHSG HD15 trial
Using the multi-agent chemotherapy regimen BEACOPP the GHSG demonstrated significantly better tumor control and overall survival compared to previously used regimens. In addition, the need for radiotherapy in patients with advanced stage Hodgkin lymphoma has been unclear.
Read more- «
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- 37
- 38
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58
- 59
- 60
- 61
- 62
- 63
- 64
- 65
- 66
- 67
- 68
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81
- 82
- 83
- 84
- 85
- 86
- 87
- 88
- 89
- 90
- 91
- 92
- 93
- 94
- 95
- 96
- 97
- 98
- 99
- 100
- 101
- 102
- 103
- 104
- 105
- 106
- 107
- 108
- 109
- 110
- 111
- 112
- 113
- 114
- »